Investors / filer profile

Legorreta Pablo G.

CEO, Chairman of the Board

active in 2 companies

Pro
Bought: Pro
Sold: 6
Filings: 2
Companies: 2026-08-05
Last filed

EDGAR · CIK 0001507678 ↗

Track record

How each disclosed position did against the S&P ~6 months later

No positions we can measure against the market yet — outcomes appear once a disclosed buy is ~6 months old.

Disclosed positions

Estimated from their latest filings — positions may have changed since

Estimated positions from their latest filingsPro →

All filings on record

Every Form 4 transaction we track for this filer


RPRXRoyalty Pharma plc	Grant — · 65,216 sh	2026-08-05	—
RPRXRoyalty Pharma plc	Grant — · 157,828 sh	2026-02-11	—
RPRXRoyalty Pharma plc	Grant — · 36,559 sh	2025-11-05	—
RPRXRoyalty Pharma plc	Grant — · 21,901 sh	2025-08-06	—
PROKPROKIDNEY CORP.	Other — · 3,823,996 sh	2025-06-03	—
PROKPROKIDNEY CORP.	Convert — · 3,823,996 sh	2025-06-03	—

RPRXGrant

2026-08-05 · Royalty Pharma plc

65,216

—

RPRXGrant

2026-02-11 · Royalty Pharma plc

157,828

—

RPRXGrant

2025-11-05 · Royalty Pharma plc

36,559

—

RPRXGrant

2025-08-06 · Royalty Pharma plc

21,901

—

PROKOther

2025-06-03 · PROKIDNEY CORP.

3,823,996

—

PROKConvert

2025-06-03 · PROKIDNEY CORP.

3,823,996

—

6 filingsEvery Form 4 on record, with outcomesPro →

Outcomes measure each position — the first buy in a stock and every buy within 182 days — against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.